Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 2
1973 1
1976 4
1977 3
1978 4
1979 2
1980 3
1981 6
1982 3
1983 6
1984 8
1985 7
1986 13
1987 5
1988 7
1989 5
1990 10
1991 10
1992 8
1993 7
1994 5
1995 13
1996 14
1997 7
1998 13
1999 12
2000 17
2001 17
2002 9
2003 10
2004 339
2005 9
2006 26
2007 46
2008 78
2009 113
2010 97
2011 130
2012 128
2013 72
2014 56
2015 57
2016 75
2017 83
2018 58
2019 64
2020 98
2021 114
2022 48
Text availability
Article attribute
Article type
Publication date

Search Results

1,436 results
Results by year
Filters applied: . Clear all
Page 1
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I. El-Khoueiry AB, et al. Among authors: chopra a. Lancet. 2017 Jun 24;389(10088):2492-2502. doi: 10.1016/S0140-6736(17)31046-2. Epub 2017 Apr 20. Lancet. 2017. PMID: 28434648 Free PMC article. Clinical Trial.
Approach to Patients with Unintentional Weight Loss.
Perera LAM, Chopra A, Shaw AL. Perera LAM, et al. Among authors: chopra a. Med Clin North Am. 2021 Jan;105(1):175-186. doi: 10.1016/j.mcna.2020.08.019. Epub 2020 Nov 7. Med Clin North Am. 2021. PMID: 33246517 Review.
Asprosin, a Fasting-Induced Glucogenic Protein Hormone.
Romere C, Duerrschmid C, Bournat J, Constable P, Jain M, Xia F, Saha PK, Del Solar M, Zhu B, York B, Sarkar P, Rendon DA, Gaber MW, LeMaire SA, Coselli JS, Milewicz DM, Sutton VR, Butte NF, Moore DD, Chopra AR. Romere C, et al. Among authors: chopra ar. Cell. 2016 Apr 21;165(3):566-79. doi: 10.1016/j.cell.2016.02.063. Epub 2016 Apr 14. Cell. 2016. PMID: 27087445 Free PMC article.
Large-Scale Multi-omic Analysis of COVID-19 Severity.
Overmyer KA, Shishkova E, Miller IJ, Balnis J, Bernstein MN, Peters-Clarke TM, Meyer JG, Quan Q, Muehlbauer LK, Trujillo EA, He Y, Chopra A, Chieng HC, Tiwari A, Judson MA, Paulson B, Brademan DR, Zhu Y, Serrano LR, Linke V, Drake LA, Adam AP, Schwartz BS, Singer HA, Swanson S, Mosher DF, Stewart R, Coon JJ, Jaitovich A. Overmyer KA, et al. Among authors: chopra a. Cell Syst. 2021 Jan 20;12(1):23-40.e7. doi: 10.1016/j.cels.2020.10.003. Epub 2020 Oct 8. Cell Syst. 2021. PMID: 33096026 Free PMC article.
Asprosin is a centrally acting orexigenic hormone.
Duerrschmid C, He Y, Wang C, Li C, Bournat JC, Romere C, Saha PK, Lee ME, Phillips KJ, Jain M, Jia P, Zhao Z, Farias M, Wu Q, Milewicz DM, Sutton VR, Moore DD, Butte NF, Krashes MJ, Xu Y, Chopra AR. Duerrschmid C, et al. Among authors: chopra ar. Nat Med. 2017 Dec;23(12):1444-1453. doi: 10.1038/nm.4432. Epub 2017 Nov 6. Nat Med. 2017. PMID: 29106398 Free PMC article.
Blood DNA methylation and COVID-19 outcomes.
Balnis J, Madrid A, Hogan KJ, Drake LA, Chieng HC, Tiwari A, Vincent CE, Chopra A, Vincent PA, Robek MD, Singer HA, Alisch RS, Jaitovich A. Balnis J, et al. Among authors: chopra a. Clin Epigenetics. 2021 May 25;13(1):118. doi: 10.1186/s13148-021-01102-9. Clin Epigenetics. 2021. PMID: 34034806 Free PMC article.
Asprosin-neutralizing antibodies as a treatment for metabolic syndrome.
Mishra I, Duerrschmid C, Ku Z, He Y, Xie W, Silva ES, Hoffman J, Xin W, Zhang N, Xu Y, An Z, Chopra AR. Mishra I, et al. Among authors: chopra ar. Elife. 2021 Apr 27;10:e63784. doi: 10.7554/eLife.63784. Elife. 2021. PMID: 33904407 Free PMC article.
1,436 results